Evidence map›Paper›PMID 27471550›Full record

ReviewDiabetology & metabolic syndrome2016

Interactions between kidney disease and diabetes: dangerous liaisons.

Roberto Pecoits-Filho, Hugo Abensur, Carolina C R Betônico, Alisson Diego Machado, Erika B Parente, Márcia Queiroz, João Eduardo Nunes Salles, Silvia Titan, Sergio Vencio

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetology & metabolic syndrome, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 3 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2020
    Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Roberto Pecoits-FilhoSchool of Medicine, Pontificia Universidade Católica do Paraná, Imaculada Conceição, 1155, Curitiba, PR 80215-901 Brazil.
Hugo AbensurSchool of Medicine, University of São Paulo, São Paulo, Brazil.
Carolina C R BetônicoHospital Regional de Presidente Prudente, Universidade do Oeste Paulista, Presidente Prudente, São Paulo, Brazil.
Alisson Diego MachadoSchool of Medicine, University of São Paulo, São Paulo, Brazil.
Erika B ParenteSanta Casa de São Paulo, São Paulo, Brazil.
Márcia QueirozSchool of Medicine, University of São Paulo, São Paulo, Brazil.
João Eduardo Nunes SallesSanta Casa de São Paulo, São Paulo, Brazil.
Silvia TitanSchool of Medicine, University of São Paulo, São Paulo, Brazil.
Sergio VencioInstitute of Pharmaceutical Sciences, Goiania, Brazil.
Universidade de São Paulo · BRPontifícia Universidade Católica do Paraná · BRUniversidade do Oeste Paulista · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (DM) globally affects 18-20 % of adults over the age of 65 years. Diabetic kidney disease (DKD) is one of the most frequent and dangerous complications of DM2, affecting about one-third of the patients with DM2. In addition to the pancreas, adipocytes, liver, and intestines, the kidneys also play an important role in glycemic control, particularly due to renal contribution to gluconeogenesis and tubular reabsorption of glucose.

methodsIn this review article, based on a report of discussions from an interdisciplinary group of experts in the areas of endocrinology, diabetology and nephrology, we detail the relationship between diabetes and kidney disease, addressing the care in the diagnosis, the difficulties in achieving glycemic control and possible treatments that can be applied according to the different degrees of impairment. DISCUSSION: Glucose homeostasis is extremely altered in patients with DKD, who are exposed to a high risk of both hyperglycemia and hypoglycemia. Both high and low glycemic levels are associated with increased morbidity and shortened survival in this group of patients. Factors that are associated with an increased risk of hypoglycemia in DKD patients include decreased renal gluconeogenesis, deranged metabolic pathways (including altered metabolism of medications) and decreased insulin clearance. On the other hand, decrease glucose filtration and excretion, and inflammation-induce insulin resistance are predisposing factors to hyperglycemic episodes.

conclusionAppropriate glycaemic monitoring and control tailored for diabetic patients is required to avoid hypoglycaemia and other glycaemic disarrays in patients with DM2 and kidney disease. Understanding the renal physiology and pathophysiology of DKD has become essential to all specialties treating diabetic patients. Disseminating this knowledge and detailing the evidence will be important to initiate breakthrough research and to encourage proper treatment of this group of patients.

Indexed as

Diabetes complicationsDiabetic kidney diseaseGlycemic controlType 2 diabetes

Identifiers

PMID27471550
PMCPMC4964290
OpenAlexW2491400284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.